<DOC>
	<DOCNO>NCT02398578</DOCNO>
	<brief_summary>Phase I/II study ass safety performance Amphora OAB system treatment urgency frequency without urge incontinence cause overactive bladder .</brief_summary>
	<brief_title>Cystoscopic Ablation Via RF Energy Clinical Trial</brief_title>
	<detailed_description>The study enroll subject symptomatic idiopathic overactive bladder ( OAB ) .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<criteria>Inclusion Criteria Subjects must meet ALL inclusion criterion eligible participate study . 1 . Nonpregnant , nonlactating female &gt; 18 year old history idiopathic OAB ≥ 6 month 2 . Have fail candidate drug treatment 3 . Subject willing provide Informed Consent , geographically stable , understands requirement complete bladder diary willing comply require diary , follow visit test schedule 4 . Ambulatory without aid walking assistance majority time ( cane , walker etc . ) able use toilet without assistance 5 . Postvoid residual ( PVR ) ≤ 100 ml NOTE : Subjects single PVR &gt; 100 ml follow two consecutive PVR measurement ≤100 ml may include study . The final acceptable PVR measurement record data . 6 . Ability willingness selfcatheterize case necessary 7 . 3 day Bladder Diary Criteria : Symptoms OAB evidence : Micturition frequency ≥ 8 times/day And &gt; 3 episode urgency urinary incontinence ( UUI ) Exclusion Criteria Subject exclude ANY follow condition apply : 1 . Planning become pregnant 12 month study period 2 . Current participation conflict interventional OAB treatment study 3 . Primary complaint stress urinary incontinence stress predominant mixed incontinence functional incontinence 4 . Any invasive surgical intervention ( e.g. , radio frequency , implant , sling ) involve bladder , rectum vaginal wall within last 6 month 5 . Ongoing complication prior antiincontinence surgery 6 . Subject 24hour total urine volume void great 3,000 ml measure screening period 7 . Receiving electrostimulation ( e.g . PTNS SNS ) treatment within last 15 day . NOTE : Subjects implant SNS device active last 15 day acceptable enrollment 8 . Botox treatment OAB 100u last 6 month OR Botox treatment &gt; 100u last 9 month 9 . Urinary tract infection resolve time enrollment &gt; 3 urinary tract infection ( UTIs ) within last 12 month NOTE : If UTI present baseline screening , treatment antibiotic negative urinalysis least 7 day initial diagnosis UTI acceptable enrollment . 10 . Documented spontaneous unprovoked urinary retention within last 6 month 11 . Anatomical condition would preclude introduction use device , opinion investigator , significant pelvic organ prolapse , urogenital prolapse visible rest beyond hymen , significant cystocele prolapse high BMI 12 . Current bleed disorder coagulopathies 13 . Current use antimuscarinics , β3 agonist antispasmodic NOTE : subject drug must undergo 2 week washout period prior complete baseline Bladder Diary . 14 . Subject previously diagnose interstitial cystitis , bladder cancer chronic pelvic pain syndrome . 15 . Previous pelvic irradiation 16 . Serum creatinine &gt; twice upper limit normal within last six month 17 . Neurological disease affect bladder function multiple sclerosis , spinal cord injury , myasthenia gravis , CharcotMarieTooth disease 18 . Current hydronephrosis hydroureter 19 . Bladder outflow obstruction 20 . Ureteral dysfunction , stricture reflux</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>